MA43943A - Compositions et procédés pour traiter des patients avec des cellules mutantes rtk - Google Patents
Compositions et procédés pour traiter des patients avec des cellules mutantes rtkInfo
- Publication number
- MA43943A MA43943A MA043943A MA43943A MA43943A MA 43943 A MA43943 A MA 43943A MA 043943 A MA043943 A MA 043943A MA 43943 A MA43943 A MA 43943A MA 43943 A MA43943 A MA 43943A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- methods
- treating patients
- mutant cells
- rtk
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562168237P | 2015-05-29 | 2015-05-29 | |
| US201662309900P | 2016-03-17 | 2016-03-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43943A true MA43943A (fr) | 2018-12-12 |
Family
ID=57441630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043943A MA43943A (fr) | 2015-05-29 | 2016-05-25 | Compositions et procédés pour traiter des patients avec des cellules mutantes rtk |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20180177792A1 (fr) |
| EP (1) | EP3303382A4 (fr) |
| JP (2) | JP6929231B2 (fr) |
| CN (1) | CN107849113B (fr) |
| AU (1) | AU2016270321B2 (fr) |
| CA (1) | CA2987281A1 (fr) |
| MA (1) | MA43943A (fr) |
| WO (1) | WO2016196141A1 (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2350075T3 (da) | 2008-09-22 | 2014-05-26 | Array Biopharma Inc | Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer |
| PT3106463T (pt) | 2008-10-22 | 2018-05-18 | Array Biopharma Inc | Compostos de pirazolo[1,5-]pirimidina substituídos como inibidores de cinase trk |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| RU2735545C2 (ru) | 2010-05-20 | 2020-11-03 | Эррэй Биофарма Инк. | Макроциклические соединения в качестве ингибиторов киназы trk |
| TWI672141B (zh) | 2014-02-20 | 2019-09-21 | 美商醫科泰生技 | 投予ros1突變癌細胞之分子 |
| EP3218380B1 (fr) | 2014-11-16 | 2021-03-17 | Array Biopharma, Inc. | Préparation d'une forme cristalline d'hydrogénosulfate de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| CN107207471B (zh) | 2014-12-02 | 2020-06-26 | 伊尼塔公司 | 用于治疗神经母细胞瘤的组合 |
| TN2019000271A1 (en) | 2015-10-26 | 2021-01-07 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| JP7061068B2 (ja) | 2015-12-18 | 2022-04-27 | イグナイタ インコーポレイテッド | 癌治療のための併用薬 |
| TN2019000332A1 (en) | 2016-04-04 | 2021-05-07 | Loxo Oncology Inc | Methods of treating pediatric cancers |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| IL304018A (en) | 2016-04-04 | 2023-08-01 | Loxo Oncology Inc | Liquid formulations of (S)-N-(5-((R)-2-(5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-A]pyrimidin-3-yl)-3 -hydroxypyrrolidine-1-carboxamide |
| ES2952056T3 (es) | 2016-05-18 | 2023-10-26 | Loxo Oncology Inc | Preparación de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| CN121401264A (zh) | 2017-07-19 | 2026-01-27 | 伊尼塔公司 | 包括恩曲替尼的药物组合物 |
| WO2019077506A1 (fr) | 2017-10-17 | 2019-04-25 | Ignyta, Inc. | Compositions pharmaceutiques et formes galéniques solides |
| SG11202007198WA (en) | 2018-01-31 | 2020-08-28 | Deciphera Pharmaceuticals Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
| EA202091763A1 (ru) | 2018-01-31 | 2020-12-14 | ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Комбинированная терапия для лечения мастоцитоза |
| EP3938363A1 (fr) | 2019-03-11 | 2022-01-19 | Teva Pharmaceuticals International GmbH | Formes à l'état solide de riprétinib |
| JP7818502B2 (ja) | 2019-08-12 | 2026-02-20 | デシフェラ・ファーマシューティカルズ,エルエルシー | 胃腸間質腫瘍を治療するためのリプレチニブ |
| WO2021030405A1 (fr) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib pour le traitement de tumeurs stromales gastro-intestinales |
| CN110643672A (zh) * | 2019-10-15 | 2020-01-03 | 西安交通大学 | 高表达TrkB作为新型靶点在抑制胰腺癌转移方面的医药用途 |
| AU2020417282B2 (en) | 2019-12-30 | 2023-08-31 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| SI4084778T1 (sl) | 2019-12-30 | 2024-01-31 | Deciphera Pharmaceuticals, Llc | Formulacije inhibitorja amorfne kinaze in načini njihove uporabe |
| US20210275518A1 (en) * | 2020-03-06 | 2021-09-09 | Deciphera Pharmaceuticals, Llc | Methods of using rebastinib in the treatment of disorders |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| CN116254253B (zh) * | 2022-11-11 | 2024-06-28 | 浙大宁波理工学院 | 一种通过dna合成改组组合突变获得的谷氨酸脱羧酶突变体及应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002275068A (ja) * | 2001-03-16 | 2002-09-25 | Kyowa Hakko Kogyo Co Ltd | アポトーシス誘導剤 |
| JP2007508801A (ja) * | 2003-10-24 | 2007-04-12 | エスバテック・アーゲー | 受容体チロシンキナーゼ阻害剤の同定および/または確認のための方法 |
| WO2006111035A1 (fr) * | 2005-04-21 | 2006-10-26 | Oncalis Ag | Methode d'identification de mutations potentiellement dangereuses du recepteur tyrosine kinase (rtk) et d'inhibiteurs ou de medicaments diriges contre les mutants de rtk |
| BRPI0614809A2 (pt) * | 2005-08-09 | 2011-04-12 | Johannes Gutenberg Universitaet Mainz | sensibilização de cánceres de pulmão resistentes a fármaco a inibidores de proteìna cinase |
| JP2010511382A (ja) * | 2006-12-01 | 2010-04-15 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | 癌関連タンパク質キナーゼ |
| EA018503B1 (ru) * | 2007-07-20 | 2013-08-30 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Замещенные производные индазола, активные как ингибиторы киназы |
| EP2294416A1 (fr) * | 2008-05-21 | 2011-03-16 | Centre National de la Recherche Scientifique - CNRS | Inhibition du récepteur nt-3:trkc lié et son application au traitement du cancer tel que le neuroblastome |
| PT3106463T (pt) * | 2008-10-22 | 2018-05-18 | Array Biopharma Inc | Compostos de pirazolo[1,5-]pirimidina substituídos como inibidores de cinase trk |
| US8383793B2 (en) * | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
| KR20140014184A (ko) * | 2011-02-25 | 2014-02-05 | 아이알엠 엘엘씨 | Trk 억제제로서의 화합물 및 조성물 |
| CN102924479A (zh) * | 2011-08-09 | 2013-02-13 | 山东鲁北药业有限公司 | 一种星孢菌素类衍生物的半合成方法 |
-
2016
- 2016-05-25 WO PCT/US2016/034166 patent/WO2016196141A1/fr not_active Ceased
- 2016-05-25 CA CA2987281A patent/CA2987281A1/fr not_active Abandoned
- 2016-05-25 CN CN201680040063.7A patent/CN107849113B/zh not_active Expired - Fee Related
- 2016-05-25 EP EP16804039.2A patent/EP3303382A4/fr not_active Withdrawn
- 2016-05-25 JP JP2017560654A patent/JP6929231B2/ja not_active Expired - Fee Related
- 2016-05-25 US US15/577,729 patent/US20180177792A1/en not_active Abandoned
- 2016-05-25 MA MA043943A patent/MA43943A/fr unknown
- 2016-05-25 AU AU2016270321A patent/AU2016270321B2/en not_active Withdrawn - After Issue
-
2021
- 2021-06-01 JP JP2021092592A patent/JP7219791B2/ja active Active
- 2021-06-23 US US17/356,128 patent/US20210322439A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6929231B2 (ja) | 2021-09-01 |
| JP7219791B2 (ja) | 2023-02-08 |
| EP3303382A4 (fr) | 2018-12-19 |
| CA2987281A1 (fr) | 2016-12-08 |
| AU2016270321B2 (en) | 2020-09-10 |
| WO2016196141A1 (fr) | 2016-12-08 |
| CN107849113A (zh) | 2018-03-27 |
| AU2016270321A2 (en) | 2018-01-04 |
| JP2021156893A (ja) | 2021-10-07 |
| AU2016270321A1 (en) | 2017-12-14 |
| JP2018521973A (ja) | 2018-08-09 |
| EP3303382A1 (fr) | 2018-04-11 |
| US20210322439A1 (en) | 2021-10-21 |
| CN107849113B (zh) | 2022-03-22 |
| US20180177792A1 (en) | 2018-06-28 |
| HK1252821A1 (zh) | 2019-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43943A (fr) | Compositions et procédés pour traiter des patients avec des cellules mutantes rtk | |
| EP3503901A4 (fr) | Procédés et compositions pour cellules de moelle épinière | |
| EP3386484A4 (fr) | Compositions et procédés permettant d'administrer des agents thérapeutiques | |
| EP3472178A4 (fr) | Compositions et procédés pour la déplétion des cellules cd117+ | |
| EP3472307A4 (fr) | Procédés et compositions de potentialisation de thérapies de cellules souches | |
| EP2961828A4 (fr) | Procédés et compositions pour mobiliser des cellules souches | |
| IL257105A (en) | Modified cells and methods of therapy | |
| SI3194570T1 (sl) | Postopki in sestavki za genomski inženiring s posredovanjem nukleaze in korekcijo krvotvornih matičnih celic | |
| SI3215601T1 (sl) | Postopki za transdukcijo in obdelavo celic | |
| HUE053485T2 (hu) | Készítmények és eljárások meibom-mirigy diszfunkció kezelésére | |
| EP2947990A4 (fr) | Compositions et procédés pour traiter des organismes nuisibles | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| IL246791A0 (en) | Compositions and methods for treating eye diseases | |
| EP3302532A4 (fr) | Compositions et procédés en rapport avec des agents biologiques antistaphylococciques | |
| EP3503879A4 (fr) | Compositions et procédés associés | |
| EP3394272A4 (fr) | Compositions et procédés permettant de cibler efficacement des transgènes | |
| EP3307284A4 (fr) | Compositions et procédés pour l'enrichissement de cellules | |
| PT3166911T (pt) | Incorporação de agentes biológicos em fertilizantes | |
| EP4012024C0 (fr) | Procédés pour améliorer la thérapie cellulaire | |
| EP3353287A4 (fr) | Compositions et procédés pour produire des cellules dendritiques | |
| PL3236960T3 (pl) | Fluralaner do zastosowania w leczeniu demodekozy | |
| EP3390641A4 (fr) | Compositions et procédés pour manipuler le développement des plantes | |
| EP3645020A4 (fr) | Compositions et procédés pour la thérapie cellulaire adoptive | |
| EP3373971A4 (fr) | Procédés et compositions pour détecter et moduler des cellules cancéreuses | |
| EP3359553A4 (fr) | Compositions et procédés pour traiter la rétinopathie diabétique |